High-Field Imri Guided Resection in Cerebral Glioma Surgery: A Prospective, Randomized, Parallel Controlled Trial
Zeyang Li,Yanyan Song,N. U. Farrukh Hameed,Shiwen Yuan,Shuai Wu,Xiu Gong,Dongxiao Zhuang,Junfeng Lu,Fengping Zhu,Tianming Qiu,Jie Zhang,Abudumijiti Aibaidula,Geng Xu,Zhong Yang,Weijun Tang,Hong Chen,Liangfu Zhou,Ying Mao,Jinsong Wu
DOI: https://doi.org/10.2139/ssrn.3944596
2021-01-01
SSRN Electronic Journal
Abstract:Background: Intraoperative magnetic resonance imaging (iMRI) enables real-time optimized extent of tumour resection (EOR) in glioma patients. However, there is no high-level evidence on its benefits. We conducted a clinical trial to assess the efficiency of iMRI-guided glioma resection.Methods: A randomized, parallel-controlled trial was launched enrolling patients with newly diagnosed cerebral glioma, aged 18-70 years, with intention to undergo gross total resection (GTR). Patients were randomly assigned to either the iMRI group or the conventional neuronavigation group (control group). The primary endpoint was the rate of GTR and the secondary endpoints were progression free survival (PFS) and overall survival (OS).Findings: A total of 321 patients were enrolled From March, 2012 to August 2018 with 161 patients randomly assigned to the iMRI group and 160 to the control group. GTR was achieved more in the iMRI group than in the control group (83.85% vs 50.00%, P = 0.0000). In the 188 high-graded glioma (HGG) patients, the rate of GTR of the iMRI group was higher than the control group (87.37% vs 56.99%, P = 0.0005). Correspondingly, the PFS of HGG patients in the iMRI group was significantly prolonged (P = 0.0017). Subgroup analysis showed that in patients with eloquent HGG, rate of GTR of the iMRI group was higher than that of the control group (88.14% vs 53.33%, P = 0.0006), which resulted in significantly longer OS in the iMRI group than in the control group (Median, 2.79 years vs 1.76 years; p=0.0282)Interpretation: This trial confirms that iMRI increases the EOR of gliomas, leading to prolonged survival of HGG, particularly in surgically challenging eloquent HGG. Achieving GTR also significantly extends the survival of HGG or IDH-wildtype diffuse glioma.Trial Registration: This trial was registered on ClinicalTrial.gov, number NCT01479686.Funding: National Key Technology R&D Program of China (No. 2014BAI04B05) and theShanghai Municipal Health Bureau (XBR2011022).Declaration of Interest: JW reports grants from National Key Technology R&D Program of China (No. 2014BAI04B05) and the Shanghai Municipal Health Bureau (XBR2011022).Ethical Approval: The Institutional Review Board of Huashan Hospital Affiliated to Fudan University (HERB). Approval No.: (2012) Clinical Review No. (008).